Adipose-derived stem cells (ASCs) are highly attractive for cell-based therapies in tissue repair and regeneration because they have multilineage differentiation capacity and are immunosuppressive. However, the detailed epigenetic mechanisms of their immunoregulatory capacity are not fully defined. In this study, we found that 
| INTRODUC TI ON
Adipose-derived stem cells (ASCs) are similar to bone marrow-derived stem cells (BMSCs) in their ability to differentiate into multiple cell types, including bone, cartilage, adipocytes and neurons. 1, 2 Additionally, ASCs are immunosuppressive and express similar surface markers to BMSCs. 6 Unlike BMSCs, clinically applicable numbers of ASCs can easily be obtained from adipose tissue collected through minimally invasive procedures such as lipoplasty. 7 Due to these properties, ASCs are appealing for use in cell-based therapies for tissue repair and regeneration.
Allogeneic ASCs are immune privileged and have immunomodulatory capabilities. In vitro, ASCs inhibit the proliferation and function of activated immune cells through cell-cell binding and paracrine signalling. 8 In vivo, ASCs have demonstrated therapeutic potential in numerous immune-mediated conditions in both pre-clinical and clinical studies, including graft-vs-host disease (GvHD) and chronic inflammatory autoimmune diseases. 9, 10 There are several possible mechanisms through which ASCs function to suppress immunity. A series of factors and molecules produced by ASCs, such as prostaglandin (PG) E2, 13 transforming growth factor-β (TGF-β) 14 and interleukin (IL)-10, 14, 15 have been shown to be critical for their immunoregulatory functions. While many of these factors have been well characterized, much remains unknown about the immunomodulatory function and therapeutic efficacy of ASCs.
Mysm1, a histone deubiquitinase, mediates the deubiquitination of lysine 119 (K119) of histone H2A, 16 and removes K63 polyubiquitins attached to TRAF3 and TRAF6. 17 We and several other groups have previously demonstrated that Mysm1 plays a crucial role in stem cell maintenance and immune cell development and function. 18, 19 Mysm1 can control essential lineage-specific developmental regulators and miRNA expression at a transcriptional level, and it regulates the p53 stress response pathway in a cell-specific manner. 25, 26 Despite these observations, knowledge of the biological functions of Mysm1 remains incomplete and its role in ASC immunoregulatory function has not been investigated.
In the present study, we demonstrate that Mysm1-deficient 
| MATERIAL S AND ME THODS

| Animals
Groups of 3-4-week-old and 8-12-week-old C57BL/6 mice were obtained from the Laboratory Animal Center of the Academy of
Military Medical Sciences of China (Beijing). Mysm1-deficient (KO) mice were generated as described previously. 18 In all experiments, age-and sex-matched wild type (WT) littermates were used for controls. Mice were maintained in a pathogen-free barrier facility.
All animal experiments were performed according to the 'Guide for 
| Immunofluorescence staining
| Carboxy fluorescein diacetate succinimidyl ester labelling
Splenocytes were isolated from C57BL/6 mice (8-12 weeks old). 
| Quantitative RT-PCR
| Lentivirus production and transduction
Recombinant lentiviral vectors containing Mysm1 or miR-150 were purchased from Genechem (Shanghai, China). Adipose-derived stem cells or C3H/10T1/2 cells were transduced as described in our previous publications.
18,25
| Chromatin immunoprecipitation
Chromatin was immunoprecipitated according to the manufactur- and TGGAGGGCTT TTCTAACAAG (reverse).
| Western blot
Cells were lysed with lysis buffer and protein samples were separated on 12% SDS-polyacrylamide gel, and then the proteins were transferred to 0.45 μm polyvinylidene fluoride blotting membranes.
The membrane was blocked in 5% non-fat dry milk for 1 hour, were then probed with primary antibodies against the proteins of interest in blocking solution overnight at 4°C, washed and then incubated in horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 hour at room temperature. Finally, enhanced chemiluminescence substrate (Thermo Fisher, Waltham, MA) was added to the membranes and the proteins were assayed according to manufacturer instructions. Antibodies against GAPDH, Mysm1 were purchased from Cell Signaling Technology, Inc.
| Induction of acute colitis
Acute colitis was induced in C57BL/6 mice by administering 3% dextran sodium sulphate (DSS; molecular weight 40 000 Da; Sigma-Aldrich) from day 0 to day 7 in drinking water. On day 1, WT and Mysm1 KO ASCs were injected intraperitoneally in DSS-treated animals. Colitis severity was assessed daily by scoring (0-4) the clinical disease activity through evaluation of stool consistency, presence of faecal blood and weight loss. Mice with acute colitis were euthanized on day 8. The entire colon was removed from the caecum to the anus, and colon length and weight were measured as indirect inflammation markers.
The macroscopic colonic damage score was assessed based on the grade of tissue adhesion, presence of ulceration and wall thickness. 
| Mouse melanoma model
| Statistical Analysis
All data were analyzed with Prism 5.0 software (GraphPad Software, San Diego, CA) and are presented as the means ± SDs. Statistical significance was assessed by unpaired two-tailed Student's t tests (*P < 0.05; **P < 0.01).
| RE SULTS
| Inflammatory cytokines induce Mysm1 expression in ASCs
Mysm1 plays essential roles in stem cell maintenance and immune cell function. Mysm1 activity has been reported in the nucleus 
| Mysm1 epigenetically regulates miR-150 expression in ASCs miR-150 is an important regulator of differentiation and activation of immune cells. Our previous studies have demonstrated that Mysm1
regulates miR-150 expression and is involved in B1a cell proliferation. 25 Here, the expression of miR-150 in KO ASCs or an Mysm1 knockdown murine MSC line was significantly lower than that in their WT counterparts ( Figure 5A ). The expression of miR-155-5p and miR-155-3p
was comparable in WT and KO ASCs, although miR-155 has been reported to regulate immune modulatory properties of MSCs. 29 We therefore focused on miR-150 for further studies. To investigate how ASCs, but not in KO ASCs ( Figure 5C ), which might account for the lower expression of pri-miR-150 in KO ASCs ( Figure 5D ).
| miR-150 regulates iNOS expression
To 
| D ISCUSS I ON
In addition to their use in tissue repair and regenerative medicine, 
| CON CLUS IONS
This study reveals that Mysm1 regulates the immunosuppressive capacity of ASCs by targeting miR-150, and thus uncovers a previously undescribed role of Mysm1 in regulating the immunomodulatory activities of ASCs. These novel insights into the mechanisms through which ASCs regulate immune reactions may help to improve the clinical utility of these cells in many inflammation related diseases.
E THI C S APPROVAL AND CON S ENT TO PARTI CIPATE
All experimental animal protocols for this study are in accordance with the national guidelines for the use of animals in scientific research. Additional approval was granted by the Animal Care and Use
Committee of the Academy of Military Medical Sciences.
F I G U R E 7
A proposed model of the mechanism by which Mysm1 regulates the immunomodulatory effect of adiposederived stem cells (ASCs). Mysm1 is induced by tumour necrosis factor-α (TNF-α) and IFNγ in ASCs. Mysm1 then promotes miR-150 transcription, which enhances inducible nitric oxide synthases (iNOS) production. Nitric oxide (NO) is catalyzed by iNOS that is essential for the immunosuppressive capacity of ASCs
